Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dotoux Plus
- Development stage
- Phase 3
- Lead developer
- Domesco Medical Import-Export
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dotoux Plus is a multi-ingredient oral medication developed and manufactured by Domesco Medical Import Export Joint Stock Corporation, a leading pharmaceutical company in Vietnam. It is formulated as a combination of three active small molecule ingredients: paracetamol (acetaminophen), phenylephrine hydrochloride, and chlorpheniramine maleate. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine acts as a sympathomimetic decongestant by stimulating alpha-1 adrenergic receptors, leading to vasoconstriction in the nasal mucosa and reducing congestion. Chlorpheniramine is a first-generation antihistamine that competitively blocks H1 receptors, alleviating symptoms such as sneezing, itching, and rhinorrhea. This combination is primarily indicated for the symptomatic relief of pain, fever, and nasal congestion associated with the common cold, influenza, and allergic rhinitis.
- Brand names
- Dotoux Plus
- Other names
- paracetamol + phenylephrine + chlorpheniramine
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Dotoux Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dotoux Plus.